Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Protamine sulfate causes endothelium-indepen-dent vasorelaxation via inducible nitric oxide syn-thase pathway

Le sulfate de protamine cause un vasorelâchement indépendant de ľendothélium par la voie de ľoxyde nitrique synthase inductible

Abstract

Purpose

The precise mechanism of systemic hypotension frequently observed with the use of protamine is unclear. Although it has been reported that protamine stimulates the release of nitric oxide (NO) from endothelium NO synthase (eNOS), the association with inducible NOS (iNOS) remains unknown, despite the induction of iNOS by lipopolysaccharides (LPS) and/or inflammatory cytokines during cardiopulmonary bypass (CPB). The purpose of this study was to determine whether protamine stimulates the release of NO from iNOS induced by LPS.

Methods

We performed prospective and controlled functional examinations with isolated endothelium-denuded thoracic aortas from 21 male Wister rats. Aortic strips were mounted in Krebs solution and treated with LPS (1 µg·mL-1) for six hours to induce iNOS. Changes in tension caused by L-arginine (a substrate of NOS), protamine or a heparin-protamine complex (heparin: protamine = 1 unit: 10 µg) were measured in strips pre-contracted by phenylephrine.

Results

No drug relaxed the strips before LPS-treatment, but each drug relaxed the strips in a dose-dependent manner after LPS-treatment (P < 0.05). Aminoguanidine (an iNOS inhibitor) and methylene blue (a guanylyl cyclase inhibitor) inhibited the relaxations.

Conclusion

These results indicate that protamine and the heparin-protamine complex stimulated the release of NO from iNOS. As iNOS is induced during CPB, protamine or a heparin-protamine complex might cause systemic hypotension, at least in part, by stimulating iNOS.

Résumé

Objectif

Le mécanisme précis de ľhypotension générale souvent observée avec ľusage de protamine n’est pas clair. Il a été démontré que la protamine stimule la libération ďoxyde nitrique (NO) à partir de la NO synthase (NOS) de ľendothélium, mais ľassociation avec la NOS inductible (NOSi) est inconnue malgré ľinduction de NOSi par les lipopolysaccharides (LPS) et/ou les cytokines inflammatoires lors de la circulation extracorporelle (CEC). Notre étude veut déterminer si la protamine stimule la libération de NO à partir de la NOSi induite par les LPS.

Méthode

Nous avons réalisé des examens fonctionnels prospectifs et contrôlés ďaortes thoraciques sans endothélium prélevées chez 21 rats mâles Wister. Les bandes aortiques ont été montées dans des solutions de Krebs et traitées avec des LPS (1 µg·mL-1) pendant six heures pour induire la NOSi. Les modifications de la tension causées par la L-arginine (un substrat de la NOS), la protamine ou un complexe ďhéparine-protamine (héparine: protamine = 1 unité 10 µg) ont été mesurées dans les bandes précontractées par la phényléphrine.

Résultats

Aucun médicament n’a détendu les bandes avant le traitement aux LPS, mais chaque médicament les a détendues en fonction de la dose après le traitement aux LPS (P < 0,05). Ľaminoguanidine (un inhibiteur de NOSi) et le bleu de méthylène (un inhibiteur de la guanylyl cyclase) ont inhibé les relâchements.

Conclusion

La protamine et le complexe ďhéparine-protamine ont stimulé la libération de NO à partir de NOSi. La NOSi étant induite pendant la CEC, la protamine ou un complexe ďhéparine-protamine peuvent, en partie, causer une hypotension générale en stimulant la NOSi.

References

  1. 1

    Horrow JC. Protamine: a review of its toxicity. Anesth Analg 1985; 64: 348–61.

  2. 2

    Shapira N, Schaff HV, Piehler JM, White RD, Still JC, Pluth JR. Cardiovascular effects of protamine sulfate in man. J Thorac Cardiovasc Surg 1982; 84: 505–14.

  3. 3

    Weiss ME, Nyhan D, Peng Z, et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 1989; 320: 886–92.

  4. 4

    Wakefield TW, Ucros I, Kresowik TF, Hinshaw DB, Stanley JC. Decreased oxygen consumption as a toxic manifestation of protamine sulfate reversal of heparin anticoagulation. J Vasc Surg 1989; 9: 772–7.

  5. 5

    Pearson PJ, Evora PR, Ayrancioglu K, Schaff HV. Protamine releases endothelium-derived relaxing factor from systemic arteries. A possible mechanism of hypotension during heparin neutralization. Circulation 1992; 86: 289–94.

  6. 6

    Ruvolo G, Greco E, Speziale G, et al. Nitric oxide formation during cardiopulmonary bypass (Letter). Ann Thorac Surg 1994; 57: 1055–7.

  7. 7

    Hayashi Y, Sawa Y, Fukuyama N, Nakazawa H, Matsuda H. Inducible nitric oxide production is an adaptation to cardiopulmonary bypass-induced inflammatory response. Ann Thorac Surg 2001; 72: 149–55.

  8. 8

    Buttery LD, Springall DR, Chester AH, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996; 75: 77–85.

  9. 9

    Takakura K, Goto Y, Kigoshi S, Muramatsu I. Comparison between the effects of treatment in vitro and in vivo with lipopolysaccharide on responsiveness of rat thoracic aorta. Circ Shock 1994; 42: 141–6.

  10. 10

    Tsuchida S, Hiraoka M, Sudo M, Kigoshi S, Muramatsu I. Attenuation of sodium nitroprusside responses after prolonged incubation of rat aorta with endotoxin. Am J Physiol 1994; 267: H2305–10.

  11. 11

    Joly GA, Ayres M, Chelly F, Kilbourn RG. Effects of NG-methyl-L-arginine, NG-nitro-L-arginine and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun 1994; 199: 147–54.

  12. 12

    Misko TP, Moore WM, Kasten TP, et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993; 233: 119–25.

  13. 13

    Martin W, Villani GM, Jothianandan D, Furchgott RF. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther 1985; 232: 708–16.

  14. 14

    Fleming I, Gray GA, Schott C, Stoclet JC. Inducible but not constitutive production of nitric oxide by vascular smooth muscle cells. Eur J Pharmacol 1991; 200: 375–6.

  15. 15

    Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a Ca2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992; 105: 575–80.

  16. 16

    Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109–42.

  17. 17

    Wan S, DeSmet JM, Barvais L, Goldstein M, Vincent JL, LeClerc JL. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996; 112: 806–11.

  18. 18

    Nandate K, Vuylsteke A, Crosbie AE, Messahel S, Oduro-Dominah A, Menon DK. Cerebrovascular cytokine responses during coronary artery bypass surgery: specific production of interleukin-8 and its attenuation by hypothermic cardiopulmonary bypass. Anesth Analg 1999; 89: 823–8.

  19. 19

    Oudemans-van Straaten HM, Jansen PG, Hoek FJ, et al. Intestinal permeability, circulating endotoxin, and postoperative systemic responses in cardiac surgery patients. J Cardiothorac Vasc Anesth 1996; 10: 187–94.

  20. 20

    Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387–9.

  21. 21

    Mayers I, Salas E, Hurst T, Johnson D, Radomski M W. Increased nitric oxide synthase activity after canine cardiopulmonary bypass is suppressed by S-nitrosoglutathione. J Thorac Cardiovasc Surg 1999; 117: 1009–16.

  22. 22

    Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery. Implications for the anesthesiologist. Anesthesiology 2002; 97: 215–52.

  23. 23

    Pevni D, Gurevich J, Frolkis I, et al. Protamine induces vasorelaxation of human internal thoracic artery by endothelial NO-synthase pathway. Ann Thorac Surg 2000; 70: 2050–3.

  24. 24

    Evora PR, Pearson PJ, Schaff HV. Protamine induces endothelium-dependent vasodilatation of the pulmonary artery. Ann Thorac Surg 1995; 60: 405–10.

  25. 25

    Komatsu H, Enzan K, Matsuura S, Kurosawa S, Mitsuhata H. Systemic hypotensive response to protamine following chronic inhibition of nitric oxide synthase in rats. Can J Anaesth 1998; 45: 1186–9.

  26. 26

    Raikar GV, Hisamochi K, Raikar BL, Schaff HV. Nitric oxide inhibition attenuates systemic hypotension produced by protamine. J Thorac Cardiovasc Surg 1996; 111: 1240–7.

  27. 27

    Carr JA, Silverman N. The heparin-protamine interaction. A review. J Cardiovasc Surg (Torino) 1999; 40: 659–66.

Download references

Author information

Correspondence to Ko Takakura or Maki Mizogami or Satoru Fukuda.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Takakura, K., Mizogami, M. & Fukuda, S. Protamine sulfate causes endothelium-indepen-dent vasorelaxation via inducible nitric oxide syn-thase pathway. Can J Anesth 53, 162–167 (2006). https://doi.org/10.1007/BF03021822

Download citation